pyruvic acid has been researched along with plx4032 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Beloueche-Babari, M; Delgado-Goni, T; Leach, MO; Marais, R; Miniotis, MF; Parkes, HG; Wantuch, S; Workman, P | 1 |
Acciardo, S; Baurain, JF; Bouzin, C; Gallez, B; Gourgue, F; Jordan, BF; Joudiou, N; Lacomblez, E; Mignion, L; Schoonjans, C | 1 |
2 other study(ies) available for pyruvic acid and plx4032
Article | Year |
---|---|
The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Energy Metabolism; Gene Expression Regulation, Enzymologic; Glucose; Humans; Indoles; Lactates; Melanoma; Metabolomics; Mitochondria; Models, Biological; Mutation; Proto-Oncogene Proteins B-raf; Pyruvate Carboxylase; Pyruvic Acid; Sulfonamides; Vemurafenib | 2016 |
Metabolic imaging using hyperpolarized
Topics: Animals; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Drug Resistance, Neoplasm; Electron Spin Resonance Spectroscopy; Female; Glycolysis; Humans; Melanoma; Mice, Nude; Oximetry; Oxygen Consumption; Proto-Oncogene Proteins B-raf; Pyruvic Acid; Transcription, Genetic; Vemurafenib; Xenograft Model Antitumor Assays | 2020 |